Daily Newsletter

28 August 2023

Daily Newsletter

28 August 2023

UK researchers develop new test for myeloid leukaemia cancers

MN-predict can forecast the likelihood of developing blood cancers, including myelodysplastic syndromes and myeloid leukaemia.

RanjithKumar Dharma August 25 2023

Researchers from the Wellcome-MRC Cambridge Stem Cell Institute (CSCI), the University of Cambridge’s Department of Haematology and the Instituto de Investigación Sanitaria del Principado de Asturias (ISPA) have developed a new test to detect individuals at risk of developing different myeloid leukaemias.

Named MN-predict, the new platform will enable doctors and scientists to detect individuals at risk early and design new treatments for preventing the development of these potentially deadly cancers.

Researchers have analysed data from over 400,000 participants in the United Kingdom Biobank.

Utilising this data, they have developed a new platform to forecast the likelihood of developing blood cancers, such as myelodysplastic syndromes, myeloproliferative neoplasms and myeloid leukaemia, over a period of 10-15 years.

Currently offered at NHS clinics, the test involves patients giving a blood sample, which is used to extract DNA for limited sequencing, along with basic blood cell counts.

With this information, MN-predict can identify individuals with a high risk of developing any of these cancers. It can be deployed within specialist clinics focused on leukaemia prevention.

The study's senior author, Professor George Vassiliou, said: “We all know that prevention is better than cure, but it is not easy to prevent diseases like leukaemia without knowing who is at risk.

“MN-predict makes it possible to identify at-risk individuals and we hope it can become an essential part of future leukaemia prevention programmes.”

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close